Tagrisso
AstraZeneca’s Tagrisso gains EU approval for lung cancer treatment
July 8, 2024Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer
AstraZeneca has announced that the EU’s European Commission (EC) has approved Tagrisso (osimertinib), with the addition of pemetrexed and platinum-based …
AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment
June 25, 2024Medical Communications AstraZeneca, Oncology, Tagrisso, chemotherapy, lung cancer
AstraZeneca has announced that Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy has been approved in Japan for the …
CHMP recommends AstraZeneca’s Tagrisso for approval for lung cancer treatment
June 3, 2024Medical Communications CHMP, EMA, Oncology, Tagrisso, lung cancer
AstraZeneca has announced that Tagrisso (osimertinib) alongside pemetrexed and platinum-based chemotherapy, has been recommended for approval in the EU for …
AstraZeneca’s Tagrisso approved by FDA for lung cancer treatment
February 19, 2024Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Tagrisso for the treatment of adult patients …
AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy
May 17, 2023Research and Development AstraZeneca, Cancer, Oncology, Tagrisso, chemotherapy
AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso (osimertinib), in combination with chemotherapy, …
FDA grants priority review to AstraZeneca’s Tagrisso as an adjuvant for early-stage EGFR-mutated non-small cell lung cancer
October 20, 2020Manufacturing and Production, Sales and Marketing AstraZeneca, FDA, Tagrisso
The FDA has revealed its decision to grant Priority Review to AstraZeneca’s Tagrisso (osimertinib) as an adjuvant treatment of patients …
NICE U-turns to approve AstraZeneca’s Tagrisso in two new lung cancer indications
September 11, 2020Medical Communications, Sales and Marketing AstraZeneca, NICE, Tagrisso
NICE has announced the recommendation of AstraZeneca’s Tagrisso (osimertinib) for routine use on the NHS in England and Wales in …
No NICE recommendation for AstraZeneca’s Tagrisso in EGFR+ lung cancer
January 22, 2020Research and Development, Sales and Marketing AstraZeneca, NICE, Tagrisso, pharma
AstraZeneca’s Tagrisso (osimertinib) has been knocked back for routine use on the NHS in England and Wales by the drug …
AZ’s Tagrisso extends median overall survival by over 3 years in metastatic, EGFR-mutated lung cancer
September 30, 2019Research and Development, Sales and Marketing AstraZeneca, Cancer, ESMO 2019, Tagrisso, lung cancer, pharma
AstraZeneca took to the stage at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona to present new …
AZ’s Tagrisso secures China approval in first-line advanced lung cancer
September 4, 2019Research and Development, Sales and Marketing AstraZeneca, China, Tagrisso, lung cancer, pharma
AstraZeneca’s Tagrisso (osimertinib) has secured approval in China from the country’s National Medical Products Administration (NMPA) in the first-line treatment …
AstraZeneca’s Tagrisso improves overall survival in lung cancer in Phase 3 trial
August 9, 2019Medical Communications AstraZeneca, Cancer, Tagrisso, lung cancer, oncology, pharma
AstraZeneca has said its cancer drug Tagrisso significantly improved overall survival in a Phase 3 study of patients with lung …
Japan approves AstraZeneca’s Tagrisso in EGFRm non-small cell lung cancer
August 21, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, Japan, Tagrisso, lung cancer, pharma
AstraZeneca has revealed that its EGFR tyrosine kinase inhibitor Tagrisso (osimertinib) has been approved in Japan by the nation’s Ministry …
EU gives nod to expanded label for AZ’s Tagrisso
June 11, 2018Sales and Marketing AstraZeneca, Tagrisso, biotech, drugs, pharma, pharmaceutical
AstraZeneca has scored another success with Tagrisso in Europe, by receiving an expanded marketing authorisation for Tagrisso in the first-line …
AZ’s Tagrisso gets FDA nod in first-line EGFR-mutated lung cancer
April 19, 2018Sales and Marketing AstraZeneca, Cancer, EGFR-TKIs, NSCLC, Tagrisso, lung cancer, pharma
AstraZeneca has announced that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) has received approval from …
Hanmi terminates lung cancer drug after being muscled out by AZ’s Tagrisso
April 13, 2018Medical Communications, Research and Development AstraZeneca, Cancer, Otila, Tagrisso, hanmi, lung cancer, pharma
South Korea’s Hanmi Pharmaceutical has announced its intention to terminate development of its lung cancer drug Olita (olmutinib) as it …
